← Antiplatelet & anticoagulant × cardiovascular events

SynthesisBMC medicine2019

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.

Georg Gelbenegger et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 164,225 people · 2019

Randomised comparison

Reduced cardiovascular events

−9%−14% to −5%

Bigger than 1 in 10 for cardiovascular events

As reported

RR 0.91, 95% CI 0.86–0.95

Randomised comparison

Reduced cardiovascular events

−14%−23% to −5%

Bigger than 3 in 10 for cardiovascular events

As reported

RR 0.86, 95% CI 0.77–0.95

Randomised comparison

Reduced cardiovascular events

−10%−18% to −1%

Bigger than 1 in 10 for cardiovascular events

As reported

RR 0.90, 95% CI 0.82–0.99

Randomised comparison

Increased cardiovascular events

+46%+30% to +64%

Bigger than 7 in 10 for cardiovascular events

As reported

RR 1.46, 95% CI 1.30–1.64

+6 more in the walkthrough ↓

Ten numbers in the abstract

the abstract, start to end

… for aspirin and control groups (RR 0.98; 95% CI, 0.93-1.02; RR 0.99; 95% CI, 0.90-1.08; …

… cardiovascular events (MACE) by 9% (RR 0.91; 95% CI, 0.86-0.95), myocardial infarction by 14% (RR 0.86; 95% CI, 0.77-0.95), and ischemic stroke by 10% (RR 0.90; 95% CI, 0.82-0.99), but was associated with a 46% relative risk increase of major bleeding events (RR 1.46; 95% CI, 1.30-1.64) compared …

… associated with a RRR of MACE by 9% (RR 0.91; 95% CI, 0.86-0.95; p …

… did not affect the risk of MACE (RR 1.11; 95% CI, 0.96-1.28; p = 0.16; …

… associated with a RRR of MACE of 11% (RR 0.89; 95% CI, 0.83-0.95; p …

… reduce the risk of MACE (RR 0.95; 95% CI, 0.88-1.02; p = 0.16; …

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
RR 0.980.93–1.02
Cardiovascular events
RR 0.990.90–1.08
Cardiovascular events
RR 0.910.86–0.95
Cardiovascular events
RR 0.860.77–0.95
Cardiovascular events
RR 0.900.82–0.99
Cardiovascular events
RR 1.461.30–1.64
Cardiovascular events
RR 0.910.86–0.95
Cardiovascular events
RR 1.110.96–1.28
Cardiovascular events
RR 0.890.83–0.95
Cardiovascular events
RR 0.950.88–1.02
Antiplatelet & anticoagulantCardiac procedures & devicesCardiovascular eventsAll-cause mortalityAdverse events & safety

Antiplatelet & anticoagulant × all-cause mortalityhelps?no deciding trial

unlikelylikely
0.25not counted

Cardiac procedures & devices × cardiovascular eventshelps?mixed

unlikelylikely
0.50not counted

Antiplatelet & anticoagulant × adverse events & safetyharms?no deciding trial

unlikelylikely
0.25not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 5

37 papers cite it

2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 31679516